Long-term safety of ixekizumab in patients with moderate-to-severe psoriasis: results from more than 17 000 patient-years of exposure

被引：0
|
作者：
Griffiths, C. E. [1 ]
Lebwohl, M. G. [2 ]
Blauvelt, A. [3 ]
Reich, K. [4 ,5 ]
Gooderham, M. [6 ]
Terui, T. [7 ]
Agada, N. [8 ]
Xu, W. [8 ]
Gallo, G. [8 ]
机构：
[1] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England
[2] Mt Sinai Hosp, New York, NY 10029 USA
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Dermatologikum Berlin, Hamburg, Germany
[5] SCIderm Res Inst, Hamburg, Germany
[6] SKiN Ctr Dermatol, Dermatol, Peterborough, ON, Canada
[7] Nihon Univ, Div Cutaneous Sci, Dept Dermatol, Sch Med, Tokyo, Japan
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷
关键词：
Ixekizumab; Psoriasis; Safety;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P005
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [1] Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
    Armstrong, April
    Paul, Carle
    Puig, Luis
    Boehncke, Wolf Henning
    Freeman, Michael
    Torii, Hideshi
    Papp, Kim
    Griffiths, Christopher E. M.
    Blauvelt, Andrew
    Reich, Kristian
    Gooderham, Melinda
    Terui, Tadashi
    Renda, Lisa
    Agada, Noah
    Xu, Wen
    Gallo, Gaia
    Lebwohl, Mark G.
    DERMATOLOGY AND THERAPY, 2020, 10 (01) : 133 - 150
  • [2] Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
    April Armstrong
    Carle Paul
    Luis Puig
    Wolf Henning Boehncke
    Michael Freeman
    Hideshi Torii
    Kim Papp
    Christopher E. M. Griffiths
    Andrew Blauvelt
    Kristian Reich
    Melinda Gooderham
    Tadashi Terui
    Lisa Renda
    Noah Agada
    Wen Xu
    Gaia Gallo
    Mark G. Lebwohl
    Dermatology and Therapy, 2020, 10 : 133 - 150
  • [3] Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
    Griffiths, Christopher E. M.
    Gooderham, Melinda
    Colombel, Jean-Frederic
    Terui, Tadashi
    Accioly, Ana P.
    Gallo, Gaia
    Zhu, Danting
    Blauvelt, Andrew
    DERMATOLOGY AND THERAPY, 2022, 12 (06) : 1431 - 1446
  • [4] Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
    Christopher E. M. Griffiths
    Melinda Gooderham
    Jean-Frederic Colombel
    Tadashi Terui
    Ana P. Accioly
    Gaia Gallo
    Danting Zhu
    Andrew Blauvelt
    Dermatology and Therapy, 2022, 12 : 1431 - 1446
  • [5] Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
    Chiricozzi, Andrea
    Megna, Matteo
    Giunta, Alessandro
    Carrera, Carlo Giovanni
    Dapavo, Paolo
    Balato, Anna
    Malagoli, Piergiorgio
    Mazzoccoli, Stella
    Parodi, Aurora
    Sabatino, Silvia
    Buzzoni, Carlotta
    Huang, Chu-Han
    Narcisi, Alessandra
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [6] Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
    Li Xia
    Zheng Jie
    Pan WeiLi
    Zheng Min
    Lu Yan
    Li FuQiu
    Ding YangFeng
    Zhang JianZhong
    Li HongYing
    Rui WenLong
    国际皮肤性病学杂志（英文）, 2022, 05 (04)
  • [7] Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
    Zheng, Jianfeng
    Chen, Wenjuan
    Yi, Xuemei
    Yu, Ning
    Ding, Yangfeng
    Gao, Yunlu
    FRONTIERS IN MEDICINE, 2023, 10
  • [8] Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
    Leonardi, Craig
    Reich, Kristian
    Foley, Peter
    Torii, Hideshi
    Gerdes, Sascha
    Guenther, Lyn
    Gooderham, Melinda
    Ferris, Laura K.
    Griffiths, Christopher E. M.
    ElMaraghy, Hany
    Crane, Heidi
    Patel, Himanshu
    Burge, Russel
    Gallo, Gaia
    Shrom, David
    Leung, Ann
    Lin, Chen-Yen
    Papp, Kim
    DERMATOLOGY AND THERAPY, 2020, 10 (03) : 431 - 447
  • [9] Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
    Craig Leonardi
    Kristian Reich
    Peter Foley
    Hideshi Torii
    Sascha Gerdes
    Lyn Guenther
    Melinda Gooderham
    Laura K. Ferris
    Christopher E. M. Griffiths
    Hany ElMaraghy
    Heidi Crane
    Himanshu Patel
    Russel Burge
    Gaia Gallo
    David Shrom
    Ann Leung
    Chen-Yen Lin
    Kim Papp
    Dermatology and Therapy, 2020, 10 : 431 - 447
  • [10] Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa
    Tzanetakou, Vassiliki
    Stergianou, Dimitra
    Giamarellos-Bourboulis, Evangelos J.
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (04) : 381 - 393
12345